| Literature DB >> 3153222 |
L Slørdal1, S Kolmannskog, P S Prytz, P J Moe, J Aarbakke.
Abstract
We have measured MTX and 7-OH-MTX in plasma and urine samples from a 9-year-old boy treated with six consecutive 24-h IV high-dose MTX courses (33.6 g/m2) after a relapse of ALL. The between-course pharmacokinetics of MTX and 7-OH-MTX were found to be highly reproducible. Both MTX and 7-OH-MTX elimination followed a biphasic curve, initial half-lives (t1/2(alpha] being 2.86 +/- 0.44 h and 5.14 +/- 0.46 h (mean +/- SD) and second-phase biological half-lives (t1/2(beta] being approximately 18 and 16 h, respectively. The apparent volume of distribution for MTX was 0.8 L/kg, whereas the corresponding value for 7-OH-MTX was threefold less. Since clearance of MTX was within the range reported for lower doses, the data suggest that MTX pharmacokinetics are not dose-dependent up to 33.6 g/m2.Entities:
Mesh:
Substances:
Year: 1986 PMID: 3153222 DOI: 10.3109/08880018609031208
Source DB: PubMed Journal: Pediatr Hematol Oncol ISSN: 0888-0018 Impact factor: 1.969